Dr Smriti Anand, Dr. A Kala


Introduction: Polycystic Ovarian Syndrome was originally described in seven women in whom the syndrome could at best be described as the combination of hirsutism, obesity, amenorrhea, and enlarged bilateral polycystic ovaries.(1) Since then, our understanding of PCOS has evolved so far that none of the originally described features is considered to be a consistent finding in PCOS—not even the appearance of numerous tiny ovarian “cysts” for which the syndrome was named.(2)

Materials and Methods: After obtaining approval of the ethics committee, a prospective, randomized, clinical controlled study was conducted for 1 and 1/2 years. Patients were randomly allocated to one of the two groups, group D (n=50),  received oral Tab Metformin 500mg BD, Tab Calcium 500mg OD, Tab Vitamin-D-1000 IU OD for 3months and group M (n=50), received oral Tab Metformin 500mg BD for 3months. Age, Menstrual irregularties, BMI, Hirsutism score Cases with hirsutism score >8, Acne, Alopesia, USG ovarian volume, S.LH, S.FSH, S. Total Calcium, S. Vitamin D and Free insulin were recorded both before treatment and after treatment in both groups. Patients were also observed for adverse reaction. Data was statistically analyzed using Epi info 7 computer software version:

Results: Both groups were comparable with regard to demographic characteristics (p>0.05). There was statistically significant difference between the two groups regarding Body Mass Index, USG ovarian volume and S.Vitamin D. However there was no statistically significant difference between the two groups regarding Menstrual irregularties, Hirsutism score Cases with hirsutism score >8, Acne, Alopesia, S.LH, S.FSH, S. Total Calcium and Free insulin.

Conclusion: This study showed the positive effects of metformin, calcium & vitamin D supplementation on Body Mass Index, Serum Vitamin D and Ovarian volume in women with polycystic ovary syndrome.


PCOS; Metformin; Vitamin D; Calcium

Full Text:



Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol.1935;29:181–91.

Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med. 2001;52:401–19.

Diamanti-Kandarakis, A survey of polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.J clin endocrinol metab 1999,84,4006-4011

Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83(9):3078–82.

Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85(7):2434–8.

Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745–9.

Farquhar CM, Birdsall M, Manning P, Mitchell JM, France JT. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aust N Z J Obstet Gynaecol.1994;34(1):67–72.

Botsis D, Kassanos D, Pyrgiotis E, Zourlas PA. Sonographic incidence of polycystic ovaries in a gynecological population. Ultrasound Obstet Gynecol. 1995;6(3):182–5.

Cresswell JL, Barker DJ, Osmond C, Egger P, Phillips DI, Fraser RB. Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet. 1997;350(9085):1131–5.

Michelmore K, Ong K, Mason S, Bennett S, Perry L, Vessey M, et al. Clinical features in women with polycystic ovaries: relationships to insulin sensitivity, insulin gene VNTR and birth weight. Clin Endocrinol (Oxf) 2001;55(4):439–46.

Firouzabadi RD, Aflatoonian A, Modarresi S, Sekhavat L, MohammadTaheri S. Therapeutic effects of calcium & vitamin D supplementation in women with PCOS. Complement Ther Clin Pract. 2012;18:85–8.

Hahn S, Haselhorst U, Tan S, Quadbeck B, Schmidt M, Roesler S, et al. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2006;114:577–83.

Muscogiuri G, Sorice GP, Prioletta A, Policola C, Della Casa S, Pontecorvi A, et al. 25-Hydroxyvitamin D concentration correlates with insulin-sensitivity and BMI in obesity. Obesity (Silver Spring)2010;18:1906–10.

Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber TR, et al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol. 2009;161:575–82.

Anagnostis P, Karras S, Goulis DG. Vitamin D in human reproduction: a narrative review. Int J Clin Pract.2013;67:225–35.

Brzozowska M, Karowicz-Bilinska A. The role of vitamin D deficiency in the etiology of polycystic ovary syndrome disorders. Ginekol Pol. 2013;84:456–60.

Thomson RL, Spedding S, Buckley JD. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012;77:343–50.

Thys-Jacobs S, Donovan D, Papadopoulos A, Sarrel P, Bilezikian JP. Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids. 1999;64:430–5.

Tehrani HG, Mostajeran F, Shahsavari S. The effect of calcium and vitamin D supplementation on menstrual cycle, body mass index and hyperandrogenism state of women with poly cystic ovarian syndrome. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2014 Sep;19(9):875.

Veena Gupta, Amrita Chaurasia*, Shazia Khatoon, Urvashi Barman Singh. A study of N-acetyl cysteine, metformin and vitamin D3 with calcium on clinical and metabolic profile in PCOS. Int J Reprod Contracept Obstet Gynecol. 2017 Oct;6(10):4372-4376


  • There are currently no refbacks.